ClinicalTrials.gg
CompletedNCT03713593Updated Feb 5, 2026Results posted

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

A Phase 3 interventional study of lenvatinib and pembrolizumab in Carcinoma, Hepatocellular, sponsored by Merck Sharp & Dohme LLC. Completed at 172 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

How we know · 7 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
794
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 36 studies testing pembrolizumab in Carcinoma, Hepatocellular — 10 open to participants now, 12 under way, 1 of them phase 3. pembrolizumab · Carcinoma, Hepatocellular.

Enrollment
3rd of 36
794 · median 54
Started
2018
with 3 others
Phase 3
7 of 36
none open now
Registered
14th of 36
by date
Lead sponsor
6 of 36
Merck Sharp & Dohme LLC

Among the 36 studies testing pembrolizumab in Carcinoma, Hepatocellular, this one is the 3rd largest by enrollment, is one of 4 that started in 2018, is one of 7 in phase 3, and was the 14th registered.

Carcinoma, Hepatocellular

3,653 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

10 of the 36 studies testing pembrolizumab in Carcinoma, Hepatocellular are open now, in 5 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing pembrolizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3745) versus lenvatinib in combination with placebo as first-line therapy for the treatment of advanced hepatocellular carcinoma in adult participants.

The primary hypotheses of this study are that lenvatinib plus pembrolizumab is superior to lenvatinib plus placebo with respect to progression-free survival (PFS) and overall survival (OS).

03

Conditions studied

  • Carcinoma, Hepatocellular

Keywords

  • receptor tyrosine kinase inhibitor
  • programmed cell death 1 (PD-1, PD1)
  • programmed cell death ligand 1 (PD-L1, PDL1)
  • programmed cell death ligand 2 (PD-L2, PDL2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is male or female and ≥18 years of age at the time of signing the
  • Has a diagnosis of hepatocellular carcinoma confirmed by radiology, histology, or cytology
  • Has Barcelona Clinic Liver Cancer (BCLC) Stage C disease, or BCLC Stage B disease not amenable to locoregional therapy or to locoregional therapy, and not amenable to a curative treatment approach
  • Has a class A liver score
  • Has a predicted of >3 months
  • Has at least one measurable hepatocellular carcinoma (HCC) lesion based on 1.1 as confirmed by BICR
  • Has an (ECOG) performance status (PS) of 0 to 1
  • Participants with will be eligible as long as their virus is well controlled

Exclusion criteria

Exclusion Criteria:

  • Has had esophageal or gastric variceal bleeding within the last 6 months
  • Has gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib
  • Has a preexisting Grade ≥3 gastrointestinal or non-gastrointestinal fistula
  • Has hemoptysis from any source or tumor bleeding within 2 weeks prior to the first dose of study intervention
  • Has significant cardiovascular impairment within 12 months of the first dose of study intervention such as history of congestive heart failure greater than (NYHA) Class II, unstable angina, myocardial infarction or cerebrovascular accident stroke, or cardiac arrhythmia associated with hemodynamic instability
  • Has had major surgery to the liver within 4 weeks prior to the first dose of study intervention
  • Has had a minor surgery (ie, simple excision) within 7 days prior to the first dose of study intervention
  • Has serious non-healing wound, ulcer, or bone fracture
  • Has received any systemic chemotherapy for HCC or chemotherapy for any in the past 3 years
  • Has received prior therapy with an anti-programmed cell death 1 (ant-), anti-programmed cell death ligand 1 (anti-PD-L1), or anti- programmed cell death ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40, or CD137)
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy or any other form of therapy within 7 days prior the first dose of study intervention
  • Has a known additional malignancy that is progressing or has required active treatment within the past 3 years with the exceptions of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that has undergone potentially curative therapy
  • Has a known history of, or any evidence of, central nervous system (CNS) and/or carcinomatous meningitis as assessed by local site investigator
  • Has severe (≥Grade 3) to study intervention and/or any of their
  • Has an active disease that has required systemic treatment in past 2 years
  • Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
  • Has urine protein ≥1 grams/24 hours
  • Prolongation of (QTc) interval to >480 milliseconds (corrected by Fridericia Formula)
  • Has (LVEF) below the institutional normal range as determined by multigated acquisition scan (MUGA) or echocardiogram (ECHO)
  • Has an active infection requiring systemic therapy with the exceptions of virus (HBV) or virus (HCV)
  • Has a known history of (HIV) infection
  • Has known active tuberculosis (Bacillus tuberculosis)
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
  • Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study intervention
  • Has had an allogenic tissue/solid organ transplant
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
794 participants (actual)

Study arms

  • Experimental
    lenvatinib plus pembrolizumab

    Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.

    Drug: lenvatinib · Biological: pembrolizumab

  • Active comparator
    lenvatinib plus placebo

    Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) orally QD plus saline placebo by IV infusion on Day 1 Q3W. Saline placebo will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.

    Drug: lenvatinib · Drug: saline placebo

Interventions

  • Administered orally once a day

    Also known as: MK-7902, E7080, LENVIMA®

  • Biologicalpembrolizumab

    Administered as an IV infusion on Day 1 Q3W

    Also known as: MK-3475, KEYTRUDA®

  • Drugsaline placebo

    Administered as an IV infusion on Day 1 Q3W

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    PFS was defined as the time from the date of the first documentation of disease progression, as determined by blinded independent central review (BICR) per RECIST 1.1 or death due to any cause (whichever occurred first). Disease progression was defined as at least 20 percent (%) increase (including an absolute increase of at least 5 millimeter \[mm\]) in the sum of diameter of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. PFS was estimated and analyzed using Kaplan-Meier method.

    Time frame: Up to approximately 41 months

  2. Overall Survival (OS)

    OS was defined as the time from randomization until death from any cause

    Time frame: Up to approximately 41 months

Secondary outcomes

  1. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    ORR was defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1 as assessed by BICR. RECIST 1.1 has been modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

    Time frame: Up to approximately 41 months

  2. Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    DOR was determined by disease assessment and is defined as the time from the first documented evidence of a response of CR or PR, per RECIST 1.1 as assessed by BICR, until the first documented disease progression or death due to any cause, whichever occurred first. RECIST 1.1 has been modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

    Time frame: Up to approximately 41 months

  3. Disease Control Rate (DCR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    DCR was defined as the percentage of participants who have a best overall response of CR, PR, or stable disease (SD) per RECIST 1.1 as assessed by BICR. SD must be achieved at ≥6 weeks after randomization to be considered best overall response. RECIST 1.1 has been modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

    Time frame: Up to approximately 41 months

  4. Time to Disease Progression (TTP) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    TTP was defined as the time from randomization to the first documented disease progression per RECIST 1.1 as assessed by BICR. RECIST 1.1 was modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ were followed.

    Time frame: Up to approximately 41 months

  5. Progression-free Survival (PFS) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

    PFS was defined as the time from the first dose of study intervention to the first documented progressive disease (PD) per mRECIST by BICR or death due to any cause, whichever occurred first. mRECIST for HCC allowed evaluation of treatment effects that were not reflected in simple total size changes of lesions. Per mRECIST, PD was defined as an increase of at least 20% in the sum of diameters (SODs) of viable (enhancing) target lesions, taking as reference the smallest SODs of viable (enhancing) target lesions recorded since the treatment started.

    Time frame: Up to approximately 41 months

  6. Objective Response Rate (ORR) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

    ORR wass defined as the percentage of participants who have a confirmed complete response (CR: disappearance of any intratumoral arterial enhancement in all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of viable \[enhancement in the arterial phase\] target lesions, taking as reference the baseline sum of the diameters of target lesions) per mRECIST as assessed by BICR. mRECIST for hepatocellular carcinoma evaluates lesions within the liver parenchyma showing increased contrast enhancement in the arterial phase. A maximum of 10 target lesions and a maximum of 5 target lesions per organ were followed.

    Time frame: Up to approximately 41 months

  7. Duration of Response (DOR) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

    DOR was determined by disease assessment and is defined as the time from the first documented evidence of a response of CR or PR, per mRECIST as assessed by BICR, until the first documented disease progression or death due to any cause, whichever occurs first. mRECIST for hepatocellular carcinoma evaluates lesions within the liver parenchyma showing increased contrast enhancement in the arterial phase. A maximum of 10 target lesions and a maximum of 5 target lesions per organ were followed.

    Time frame: Up to approximately 41 months

  8. Disease Control Rate (DCR) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

    DCR was defined as the percentage of participants who have a best overall response of CR, PR, or SD per mRECIST as assessed by BICR. mRECIST for hepatocellular carcinoma evaluates lesions within the liver parenchyma showing increased contrast enhancement in the arterial phase. SD must be achieved at ≥6 weeks after randomization to be considered best overall response. A maximum of 10 target lesions and a maximum of 5 target lesions per organ were followed.

    Time frame: Up to approximately 41 months

  9. Time to Disease Progression (TTP) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

    TTP was defined as the time from randomization to the first documented disease progression per mRECIST as assessed by BICR. mRECIST for hepatocellular carcinoma evaluates lesions within the liver parenchyma showing increased contrast enhancement in the arterial phase. A maximum of 10 target lesions and a maximum of 5 target lesions per organ were followed.

    Time frame: Up to approximately 41 months

  10. Number of Participants Who Experienced an Adverse Event (AE)

    Number of participants who experienced an AE defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study therapy and irrespective of causality to study treatment

    Time frame: Up to approximately 68 months

  11. Number of Participants Who Experienced an Serious Adverse Event (SAE)

    Number of participants who experienced a SAE defined as an AE that resulted in death, was life threatening, resulting in persistent or significant disability or incapacity, resulting in or prolonged a hospitalization, was a congenital anomaly or birth defect, was a cancer, was associated with an overdose, or was another important medical event

    Time frame: Up to approximately 68 months

  12. Number of Participants Who Experienced an Immune-related Adverse Event (irAE) of Clinical Interest

    Number of participants who experienced an AE representing an immunologic etiology and considered to be causally related to drug exposure

    Time frame: Up to approximately 41 months

  13. Number of Participants Who Experienced an Hepatic Event of Clinical Interest (HECI)

    Number of participants who experienced a hepatic ECI not due to disease progression as judged by the investigator.

    Time frame: Up to approximately 68 months

  14. Number of Participants Who Discontinued Study Drug Due to an Adverse Event

    Number of participants who discontinued study treatment due to an AE

    Time frame: Up to approximately 68 months

07

Results

Posted Jul 24, 2023

Participant flow

Participants with a radiologically, histologically- or cytologically-confirmed diagnosis of hepatocellular carcinoma (HCC) were recruited into this study.

Participant flow — Overall Study
MilestoneLenvatinib + PembrolizumabLenvatinib + Placebo
Started395399
Completed00
Not completed395399
Withdrew: Sponsor decision7341
Withdrew: Lost to follow-up21
Withdrew: Death314349
Withdrew: Withdrawal by subject68

Outcome measures

PrimaryProgression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

PFS was defined as the time from the date of the first documentation of disease progression, as determined by blinded independent central review (BICR) per RECIST 1.1 or death due to any cause (whichever occurred first). Disease progression was defined as at least 20 percent (%) increase (including an absolute increase of at least 5 millimeter \[mm\]) in the sum of diameter of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. PFS was estimated and analyzed using Kaplan-Meier method.

Time frame:
Up to approximately 41 months
Reported as:
Median · Months
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
MonthsLenvatinib + PembrolizumabLenvatinib + Placebo
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)8.2 (6.3 to 8.3)8.1 (6.3 to 8.3)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo · Hazard ratio (hr): 0.834 · 95% CI 0.712 to 0.978Based on Cox model with Efron's method of tie handling with treatment as a covariate stratified by geographic region, MPVI or extrahepatic spread or both, AFP and ECOG PS.
PrimaryOverall Survival (OS)

OS was defined as the time from randomization until death from any cause

Time frame:
Up to approximately 41 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsLenvatinib + PembrolizumabLenvatinib + Placebo
Overall Survival (OS)21.2 (19.0 to 23.6)19.0 (17.2 to 21.7)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo · Log Rank · p = 0.0227 · Hazard ratio (hr): 0.840 · 95% CI 0.708 to 0.997Based on Cox model with Efron's method of tie handling with treatment as a covariate stratified by geographic region, MPVI or extrahepatic spread or both, AFP and ECOG PS.
SecondaryObjective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

ORR was defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1 as assessed by BICR. RECIST 1.1 has been modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

Time frame:
Up to approximately 41 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Percentage of ParticipantsLenvatinib + PembrolizumabLenvatinib + Placebo
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)26.1 (21.8 to 30.7)17.5 (13.9 to 21.6)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo · Difference in percentage: 8.5 · 95% CI 2.8 to 14.2Based on Miettinen \& Nurminen method stratified by geographic region, MPVI or extrahepatic spread or both, AFP and ECOG PS.
SecondaryDuration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

DOR was determined by disease assessment and is defined as the time from the first documented evidence of a response of CR or PR, per RECIST 1.1 as assessed by BICR, until the first documented disease progression or death due to any cause, whichever occurred first. RECIST 1.1 has been modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

Time frame:
Up to approximately 41 months
Reported as:
Median · Months
Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
MonthsLenvatinib + PembrolizumabLenvatinib + Placebo
Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)4.1 (1.3 to 25.3)4.0 (0.3 to 18.6)
SecondaryDisease Control Rate (DCR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

DCR was defined as the percentage of participants who have a best overall response of CR, PR, or stable disease (SD) per RECIST 1.1 as assessed by BICR. SD must be achieved at ≥6 weeks after randomization to be considered best overall response. RECIST 1.1 has been modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

Time frame:
Up to approximately 41 months
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Percentage of ParticipantsLenvatinib + PembrolizumabLenvatinib + Placebo
Disease Control Rate (DCR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)81.3 (77.1 to 85.0)78.4 (74.1 to 82.4)
SecondaryTime to Disease Progression (TTP) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

TTP was defined as the time from randomization to the first documented disease progression per RECIST 1.1 as assessed by BICR. RECIST 1.1 was modified for this study to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ were followed.

Time frame:
Up to approximately 41 months
Reported as:
Median · Months
Time to Disease Progression (TTP) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
MonthsLenvatinib + PembrolizumabLenvatinib + Placebo
Time to Disease Progression (TTP) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)8.3 (8.1 to 10.3)8.2 (7.0 to 8.4)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo · Hazard ratio (hr): 0.79 · 95% CI 0.66 to 0.93Based on Cox model with Efron's method of tie handling with treatment as a covariate stratified by geographic region, MPVI or extrahepatic spread or both, AFP and ECOG PS.
SecondaryProgression-free Survival (PFS) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

PFS was defined as the time from the first dose of study intervention to the first documented progressive disease (PD) per mRECIST by BICR or death due to any cause, whichever occurred first. mRECIST for HCC allowed evaluation of treatment effects that were not reflected in simple total size changes of lesions. Per mRECIST, PD was defined as an increase of at least 20% in the sum of diameters (SODs) of viable (enhancing) target lesions, taking as reference the smallest SODs of viable (enhancing) target lesions recorded since the treatment started.

Time frame:
Up to approximately 41 months
Reported as:
Median · Months
Progression-free Survival (PFS) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
MonthsLenvatinib + PembrolizumabLenvatinib + Placebo
Progression-free Survival (PFS) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)8.4 (8.2 to 10.2)8.1 (6.5 to 8.3)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo · Hazard ratio (hr): 0.80 · 95% CI 0.68 to 0.94Based on Cox model with Efron's method of tie handling with treatment as a covariate stratified by geographic region, MPVI or extrahepatic spread or both, AFP and ECOG PS.
SecondaryObjective Response Rate (ORR) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

ORR wass defined as the percentage of participants who have a confirmed complete response (CR: disappearance of any intratumoral arterial enhancement in all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of viable \[enhancement in the arterial phase\] target lesions, taking as reference the baseline sum of the diameters of target lesions) per mRECIST as assessed by BICR. mRECIST for hepatocellular carcinoma evaluates lesions within the liver parenchyma showing increased contrast enhancement in the arterial phase. A maximum of 10 target lesions and a maximum of 5 target lesions per organ were followed.

Time frame:
Up to approximately 41 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
Percentage of ParticipantsLenvatinib + PembrolizumabLenvatinib + Placebo
Objective Response Rate (ORR) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)40.8 (35.9 to 45.8)34.1 (29.4 to 39.0)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo · Difference in percentage: 6.7 · 95% CI 0.0 to 13.4Based on Miettinen \& Nurminen method stratified by geographic region, MPVI or extrahepatic spread or both, AFP and ECOG PS.
SecondaryDuration of Response (DOR) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

DOR was determined by disease assessment and is defined as the time from the first documented evidence of a response of CR or PR, per mRECIST as assessed by BICR, until the first documented disease progression or death due to any cause, whichever occurs first. mRECIST for hepatocellular carcinoma evaluates lesions within the liver parenchyma showing increased contrast enhancement in the arterial phase. A maximum of 10 target lesions and a maximum of 5 target lesions per organ were followed.

Time frame:
Up to approximately 41 months
Reported as:
Median · Months
Duration of Response (DOR) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
MonthsLenvatinib + PembrolizumabLenvatinib + Placebo
Duration of Response (DOR) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)2.1 (1.2 to 16.6)2.1 (0.2 to 14.5)
SecondaryDisease Control Rate (DCR) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

DCR was defined as the percentage of participants who have a best overall response of CR, PR, or SD per mRECIST as assessed by BICR. mRECIST for hepatocellular carcinoma evaluates lesions within the liver parenchyma showing increased contrast enhancement in the arterial phase. SD must be achieved at ≥6 weeks after randomization to be considered best overall response. A maximum of 10 target lesions and a maximum of 5 target lesions per organ were followed.

Time frame:
Up to approximately 41 months
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
Percentage of ParticipantsLenvatinib + PembrolizumabLenvatinib + Placebo
Disease Control Rate (DCR) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)84.3 (80.3 to 87.7)83.2 (79.2 to 86.7)
SecondaryTime to Disease Progression (TTP) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

TTP was defined as the time from randomization to the first documented disease progression per mRECIST as assessed by BICR. mRECIST for hepatocellular carcinoma evaluates lesions within the liver parenchyma showing increased contrast enhancement in the arterial phase. A maximum of 10 target lesions and a maximum of 5 target lesions per organ were followed.

Time frame:
Up to approximately 41 months
Reported as:
Median · Months
Time to Disease Progression (TTP) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
MonthsLenvatinib + PembrolizumabLenvatinib + Placebo
Time to Disease Progression (TTP) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST)10.4 (8.5 to 11.7)8.3 (8.1 to 8.9)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Lenvatinib + Placebo · Hazard ratio (hr): 0.73 · 95% CI 0.61 to 0.88Based on Cox model with Efron's method of tie handling with treatment as a covariate stratified by geographic region, MPVI or extrahepatic spread or both, AFP and ECOG PS.
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

Number of participants who experienced an AE defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study therapy and irrespective of causality to study treatment

Time frame:
Up to approximately 68 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsLenvatinib + PembrolizumabLenvatinib + Placebo
Number of Participants Who Experienced an Adverse Event (AE)394392
SecondaryNumber of Participants Who Experienced an Serious Adverse Event (SAE)

Number of participants who experienced a SAE defined as an AE that resulted in death, was life threatening, resulting in persistent or significant disability or incapacity, resulting in or prolonged a hospitalization, was a congenital anomaly or birth defect, was a cancer, was associated with an overdose, or was another important medical event

Time frame:
Up to approximately 68 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Serious Adverse Event (SAE)
ParticipantsLenvatinib + PembrolizumabLenvatinib + Placebo
Number of Participants Who Experienced an Serious Adverse Event (SAE)185159
SecondaryNumber of Participants Who Experienced an Immune-related Adverse Event (irAE) of Clinical Interest

Number of participants who experienced an AE representing an immunologic etiology and considered to be causally related to drug exposure

Time frame:
Up to approximately 41 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Immune-related Adverse Event (irAE) of Clinical Interest
ParticipantsLenvatinib + PembrolizumabLenvatinib + Placebo
Number of Participants Who Experienced an Immune-related Adverse Event (irAE) of Clinical Interest210184
SecondaryNumber of Participants Who Experienced an Hepatic Event of Clinical Interest (HECI)

Number of participants who experienced a hepatic ECI not due to disease progression as judged by the investigator.

Time frame:
Up to approximately 68 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Hepatic Event of Clinical Interest (HECI)
ParticipantsLenvatinib + PembrolizumabLenvatinib + Placebo
Number of Participants Who Experienced an Hepatic Event of Clinical Interest (HECI)7177
SecondaryNumber of Participants Who Discontinued Study Drug Due to an Adverse Event

Number of participants who discontinued study treatment due to an AE

Time frame:
Up to approximately 68 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Drug Due to an Adverse Event
ParticipantsLenvatinib + PembrolizumabLenvatinib + Placebo
Number of Participants Who Discontinued Study Drug Due to an Adverse Event5141

Adverse events

Collected over Up to ~ 68 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib + Pembrolizumab314/395 (79.5%)185/395 (46.8%)390/395 (98.7%)
Lenvatinib + Placebo352/399 (88.2%)159/395 (40.3%)388/395 (98.2%)
Most frequent serious events
Showing 10 of 270
Most frequent serious events
EventLenvatinib + PembrolizumabLenvatinib + Placebo
Hepatic encephalopathyNervous system disorders21/39511/395
DiarrhoeaGastrointestinal disorders13/3955/395
AscitesGastrointestinal disorders5/39510/395
Abdominal painGastrointestinal disorders8/3954/395
Hepatic failureHepatobiliary disorders4/3958/395
PneumoniaInfections and infestations8/3957/395
General physical health deteriorationGeneral disorders7/3950/395
AnaemiaBlood and lymphatic system disorders5/3951/395
Oesophageal varices haemorrhageGastrointestinal disorders0/3955/395
DeathGeneral disorders5/3953/395
Most frequent other events
Showing 10 of 64
Most frequent other events
EventLenvatinib + PembrolizumabLenvatinib + Placebo
HypertensionVascular disorders180/395200/395
DiarrhoeaGastrointestinal disorders187/395167/395
HypothyroidismEndocrine disorders167/395159/395
ProteinuriaRenal and urinary disorders136/395153/395
Decreased appetiteMetabolism and nutrition disorders146/395120/395
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders133/395125/395
FatigueGeneral disorders126/39598/395
Weight decreasedInvestigations121/39590/395
Aspartate aminotransferase increasedInvestigations117/395105/395
Platelet count decreasedInvestigations101/395110/395

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Lenvatinib + PembrolizumabLenvatinib + PlaceboTotal
Mean64.2 ± 10.964.1 ± 12.164.1 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib + PembrolizumabLenvatinib + PlaceboTotal
Female7872150
Male317327644
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lenvatinib + PembrolizumabLenvatinib + PlaceboTotal
Hispanic or Latino484189
Not Hispanic or Latino334349683
Unknown or Not Reported13922
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lenvatinib + PembrolizumabLenvatinib + PlaceboTotal
American Indian or Alaska Native13821
Asian172173345
Native Hawaiian or Other Pacific Islander202
Black or African American5813
White173172345
More than one race121022
Unknown or Not Reported182846
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Lenvatinib + PembrolizumabLenvatinib + PlaceboTotal
ECOG = 0267271538
ECOG = 1127126253
ECOG = 2101
Missing022
Geographic Region
Geographic Region(Participants)Lenvatinib + PembrolizumabLenvatinib + PlaceboTotal
Asia without Japan121123244
Japan and Western regions274276550
08

Study locations

172 sites
  • The University of Arizona Cancer Center - North Campus ( Site 0621)
    Tucson, Arizona 85721, United States
  • City of Hope Comprehensive Cancer Center ( Site 0587)
    Duarte, California 91010, United States
  • Scripps Health ( Site 0644)
    La Jolla, California 92037, United States
  • Pacific Hematology Oncology Associates ( Site 0588)
    San Francisco, California 94115, United States
  • UCLA ( Site 0589)
    Santa Monica, California 90404, United States
  • Georgetown University ( Site 0594)
    Washington D.C., District of Columbia 20007, United States
  • University of Miami, Sylvester Comprehensive Cancer Center ( Site 0596)
    Miami, Florida 33136, United States
  • Advent Health ( Site 0595)
    Orlando, Florida 32804, United States
  • Tampa General Medical Group ( Site 0629)
    Tampa, Florida 33606, United States
  • Emory University Winship Cancer Institute ( Site 0639)
    Atlanta, Georgia 30322, United States
  • University of Kansas Cancer Center ( Site 0600)
    Westwood, Kansas 66205, United States
  • Massachusetts General Hospital ( Site 0603)
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center ( Site 0716)
    Boston, Massachusetts 02215, United States
  • Icahn School of Medicine at Mount Sinai ( Site 0611)
    New York, New York 10029, United States
  • University of Rochester ( Site 0613)
    Rochester, New York 14642, United States
  • Stony Brook University Medical Center - Cancer Center ( Site 0612)
    Stony Brook, New York 11794, United States
  • University of Oklahoma Health Science Center ( Site 0625)
    Oklahoma City, Oklahoma 73104, United States
  • Oregon Health & Science University ( Site 0645)
    Portland, Oregon 97239, United States
  • Eastern Regional Medical Center, Inc. ( Site 0626)
    Philadelphia, Pennsylvania 19124, United States
  • Central Texas Veterans Healthcare System ( Site 0617)
    Temple, Texas 76504, United States
  • Cancer Care Northwest ( Site 0636)
    Spokane, Washington 99218, United States
  • Royal Prince Alfred Hospital ( Site 0001)
    Camperdown, New South Wales 2050, Australia
  • Princess Alexandra Hospital ( Site 0007)
    Wooloongabba, Queensland 4102, Australia
  • Monash Health-Monash Medical Centre ( Site 0004)
    Clayton, Victoria 3168, Australia
  • St Vincents Hospital Melbourne ( Site 0003)
    Fitzroy, Victoria 3065, Australia
  • Liverpool Hospital. ( Site 0002)
    Liverpool, 2170, Australia
  • BC Cancer-Vancouver Center ( Site 0056)
    Vancouver, British Columbia V5Z 4E6, Canada
  • London Health Sciences Centre ( Site 0053)
    London, Ontario N6A 5A5, Canada
  • Sunnybrook Research Institute ( Site 0055)
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Cancer Centre ( Site 0050)
    Toronto, Ontario M5G 2M9, Canada
  • McGill University Health Centre ( Site 0052)
    Montreal, Quebec H4A 3J1, Canada
  • Clinica Universidad Catolica del Maule ( Site 0065)
    Talca, Maule Region 3465584, Chile
  • Fundacion Arturo Lopez Perez ( Site 0064)
    Santiago, Santiago Metropolitan 7500921, Chile
  • Pontificia Universidad Catolica de Chile ( Site 0070)
    Santiago, Santiago Metropolitan 8330024, Chile
  • Instituto Clinico Oncologico del Sur ( Site 0067)
    Temuco, 4810469, Chile
  • First Affiliated Hospital of Anhui Medical University ( Site 0095)
    Hefei, Anhui 230088, China
  • Cancer Hospital Chinese Academy of Medical Sciences ( Site 0100)
    Beijing, Beijing Municipality 100021, China
  • Beijing Cancer Hospital ( Site 0088)
    Beijing, Beijing Municipality 100142, China
  • 900 Hospital of the Joint ( Site 0091)
    Fuzhou, Fujian 350025, China
  • Guangdong General Hospital ( Site 0092)
    Guangzhou, Guangdong 510080, China
  • Southern Medical University Nanfang Hospital ( Site 0102)
    Guangzhou, Guangdong 510515, China
  • Harbin Medical University Cancer Hospital ( Site 0089)
    Harbin, Heilongjiang 610000, China
  • Wuhan Union hospital Cancer Center ( Site 0105)
    Wuhan, Hubei 430022, China
  • Hunan Cancer Hospital ( Site 0094)
    Changsha, Hunan 410006, China
  • The Third Xiangya Hospital of Central South University ( Site 0093)
    Changsha, Hunan 410013, China
  • The 81st Hospital of PLA ( Site 0085)
    Nanjing, Jiangsu 210031, China
  • Fudan University Shanghai Cancer Center ( Site 0086)
    Shanghai, Shanghai Municipality 200032, China
  • The First Affiliated Hospital of Xi an Jiaotong University ( Site 0090)
    Xi’an, Shanxi 710061, China
  • West China Hospital of Sichuan University ( Site 0087)
    Chengdu, Sichuan 610000, China
  • Affiliated Tumor Hospital of Xinjiang Medical University ( Site 0109)
    Ürümqi, Xinjiang 830001, China
  • The First Affiliated Hospital of Zhejiang University ( Site 0097)
    Hangzhou, Zhejiang 310003, China
  • Sir Run Run Shaw Hospital ( Site 0110)
    Hangzhou, Zhejiang 310016, China
  • Zhejiang Cancer Hospital ( Site 0101)
    Hangzhou, Zhejiang 310022, China
  • Zhongshan Hospital Fudan University ( Site 0096)
    Shanghai, 200032, China
  • Fundacion Centro de Investigacion Clinica CIC ( Site 0141)
    Medellín, Antioquia 050021, Colombia
  • Hospital Pablo Tobon Uribe ( Site 0144)
    Medellín, Antioquia 050034, Colombia
  • Hospital General de Medellin Luz Castro de Gutierrez ( Site 0137)
    Medellín, Antioquia 500515, Colombia
  • Biomelab S A S ( Site 0145)
    Barranquilla, Atlántico 080002, Colombia
  • Administradora Country SA - Clinica del Country ( Site 0146)
    Bogotá, Bogota D.C. 110221, Colombia
  • Instituto Nacional de Cancerologia E.S.E ( Site 0142)
    Bogotá, Bogota D.C. 111511, Colombia
  • Fundacion Valle del Lili ( Site 0140)
    Cali, Valle del Cauca Department 760032, Colombia
  • Centro Medico Imbanaco de Cali S.A ( Site 0139)
    Cali, Valle del Cauca Department 760042, Colombia
  • Institut Sainte Catherine ( Site 0167)
    Avignon, 84918, France
  • Hopital Beaujon ( Site 0160)
    Clichy, 92110, France
  • CHU Henri Mondor ( Site 0162)
    Créteil, 94000, France
  • CHRU de Lille - Hopital Claude Huriez ( Site 0159)
    Lille, 59037, France
  • Hopital de la Croix Rousse ( Site 0157)
    Lyon, 69004, France
  • Hopital Saint Joseph ( Site 0166)
    Marseille, 13285, France
  • Centre Hospitalier Regional du Orleans ( Site 0169)
    Orléans, 45100, France
  • Centre Eugene Marquis ( Site 0158)
    Rennes, 35042, France
  • CHU de Nancy Hopital Brabois Adultes ( Site 0164)
    Vandœuvre-lès-Nancy, 54500, France
  • Klinikum der Universitaet Aachen - RWTH ( Site 0185)
    Aachen, 52074, Germany
  • Universitaetsklinik Koeln ( Site 0189)
    Cologne, 50937, Germany
  • Universitaetsklinikum Carl Gustav Carus der TU Dresden ( Site 0178)
    Dresden, 01307, Germany
  • Universitaetsklinikum Essen ( Site 0188)
    Essen, 45147, Germany
  • Universitaetsklinikum Frankfurt ( Site 0180)
    Frankfurt am Main, 60596, Germany
  • Universitaetsklinikum Hamburg-Eppendorf ( Site 0184)
    Hamburg, 20246, Germany
  • Universitaetsklinikum Leipzig ( Site 0187)
    Leipzig, 04103, Germany
  • Otto-Von-Guericke-Universitaet Magdeburg ( Site 0182)
    Magdeburg, 39120, Germany
  • Universitaetsklinikum Tuebingen ( Site 0179)
    Tübingen, 72076, Germany
  • Universitaetsklinikum Wuerzburg ( Site 0186)
    Würzburg, 97080, Germany
  • St Vincents University Hospital ( Site 0242)
    Dublin, D04 T6F4, Ireland
  • Mater Misericordiae University Hospital ( Site 0241)
    Dublin, D07 R2WY, Ireland
  • Ospedale Sacro Cuore - Don Calabria ( Site 0289)
    Negrar, VR 37024, Italy
  • Centro di Riferimento Oncologico de Aviano Istituto Nazionale Tumori ( Site 0292)
    Aviano, 33081, Italy
  • Policlinico S. Orsola-Malpighi ( Site 0286)
    Bologna, 40138, Italy
  • Istituto Oncologico Veneto ( Site 0287)
    Padova, 35128, Italy
  • Az Osp Univ Policlin Paolo Giaccone ( Site 0284)
    Palermo, 90127, Italy
  • Fondazione Salvatore Maugeri IRCCS. ( Site 0290)
    Pavia, 27100, Italy
  • Azienda Ospedaliero-Univers. Pisana Ospedale S. Chiara ( Site 0291)
    Pisa, 56126, Italy
  • Policlinico Universitario Campus Biomedico ( Site 0288)
    Roma, 00128, Italy
  • Aichi Cancer Center Hospital ( Site 0316)
    Nagoya, Aichi-ken 464-8681, Japan
  • National Cancer Center Hospital East ( Site 0306)
    Kashiwa, Chiba 277-8577, Japan
  • Kurume University Hospital ( Site 0322)
    Kurume, Fukuoka 830-0011, Japan
  • Hokkaido P.W.F.A.C Sapporo-Kosei General Hospital ( Site 0304)
    Sapporo, Hokkaido 060-0033, Japan
  • Kanazawa University Hospital ( Site 0315)
    Kanazawa, Ishikawa-ken 920-8641, Japan
  • Kagawa University Hospital ( Site 0324)
    Kita-gun, Kagawa-ken 761-0793, Japan
  • Kagawa Prefectural Central Hospital ( Site 0325)
    Takamatsu, Kagawa-ken 760-8557, Japan
  • Toranomon Hospital Kajigaya ( Site 0312)
    Kawasaki, Kanagawa 213-8587, Japan
  • Yokohama City University Medical Center ( Site 0313)
    Yokohama, Kanagawa 232-0024, Japan

Showing the first 100 of 172 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. PubMed 38039993 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Jun 2022, 41 months.

Results were first posted in Jul 2023, 1 year 1 month after primary completion.

Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 41 months is below that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2018
First posted
Oct 22, 2018
StartActual
Dec 31, 2018
Primary completionActual
Jun 21, 2022
CompletionActual
Sep 24, 2024
Results first posted
Jul 24, 2023
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03713593
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Oct 22, 2018
Start date
Dec 31, 2018
Primary completion
Jun 21, 2022
Completion
Sep 24, 2024
Results posted
Jul 24, 2023
Last update
Feb 5, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion